Impact Biomedical IBO Income Statement (2022-2026)

NYSE IBO
$0.46 -0.03 (-7.15%)
As of: Sep 10, 2026 · 3:57 PM EDT
Reported Financials

Impact Biomedical Quarterly Income Statement

Periods 17 quarters
Latest Jun 2026

Impact Biomedical reported revenue of $0.00M and net income of -$0.70M for the quarter ended Jun 2026, down 57.1% year over year. This income statement covers 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue 0.05M0.01M0.02M0.01M0.00M
Cost of RevenueCost of Rev 0.00M0.00M0.00M
Gross Profit 0.01M0.02M0.00M
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot) 0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M
Research & DevelopmentR&D 0.21M0.33M0.52M0.18M0.27M0.36M0.63M0.18M0.12M0.46M0.15M0.10M0.07M0.05M0.05M0.08M
Selling, General & AdministrativeSG&A 0.06M0.09M0.04M0.04M0.04M0.10M0.13M0.15M0.14M0.13M0.29M0.25M0.25M0.26M-0.44M1.62M0.17M
Restructuring CostsRestructuring 0.03M0.01M0.03M0.01M0.02M0.12M
Other Operating ExpensesOther Opex 0.51M0.46M0.44M0.58M0.69M0.60M0.25M0.44M0.36M0.53M25.79M0.66M0.84M0.65M0.63M0.46M
Operating ExpensesOpex 0.80M0.89M1.03M0.80M1.01M1.08M1.14M0.77M0.63M1.13M26.23M1.01M1.16M0.97M-0.44M2.30M0.70M
Operating IncomeOp. Inc -0.75M-0.89M-1.03M-0.80M-1.01M-1.08M-1.14M-0.77M-0.63M-1.13M-26.23M-1.01M-1.15M-0.95M-2.29M-0.70M
EBIT -0.75M-0.89M-1.03M-0.80M-1.01M-1.08M-1.14M-0.77M-0.63M-1.13M-26.23M-1.01M-1.15M-0.95M-2.29M-0.70M
Non-operating items
Non Operating Interest Expenses 0.14M0.09M0.10M0.10M0.12M0.10M0.12M0.23M0.26M0.30M0.27M0.27M0.26M0.26M0.07M0.07M
Interest & Investment IncomeInt & Inv Inc 0.09M0.00M-0.08M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.01M0.00M
Other Non Operating IncomeOther Non Op Inc. 0.05M5.67M
Net income details
EBT -0.80M-0.98M-5.25M-0.85M-1.12M-1.18M-1.26M-1.00M-0.88M4.24M-27.10M-1.28M-14.35M-1.48M-2.28M-0.70M
Tax ProvisionsTaxes 1.26M-1.88M
Profit After TaxPAT -0.80M-2.24M-3.37M-0.85M-1.12M-1.18M-1.26M-1.00M-0.89M4.25M-27.17M-1.28M-14.35M-1.48M-2.29M-0.70M
Income from Non-Controlling InterestsInc. Minority -0.07M-0.07M0.20M-0.19M-0.02M-0.01M-0.03M-0.04M0.01M-0.01M-0.03M-0.01M-0.01M-0.01M0.00M-0.00M
Income from Continuing OperationsIncome (Continuing) -0.80M-2.24M-3.37M-0.85M-1.12M-1.18M-1.26M-1.00M-0.88M4.24M-27.10M-1.28M-14.35M-1.48M-2.28M-0.70M
Consolidated Net IncomeConsol Net Inc. -0.80M-2.24M-3.37M-0.85M-1.12M-1.18M-1.26M-1.00M-0.88M4.24M-27.10M-1.28M-14.35M-1.48M-2.28M-0.70M
Income towards Parent CompanyParent Net Inc -0.80M-2.24M-3.37M-0.85M-1.12M-1.18M-1.26M-1.00M-0.88M4.24M-27.10M-1.28M-14.35M-1.48M-2.28M-0.70M
Net Income towards Common StockholdersNet Income -0.73M-2.17M-3.36M-0.66M-1.10M-1.16M-1.24M-0.96M-0.89M4.25M-27.10M-1.28M-14.35M-1.48M-2.28M-0.70M
Additional items
EPS (Basic) 0.00-0.03-0.05-0.01-0.02-0.02-0.02-0.10-0.090.37-2.52-0.11-1.18-0.12-0.02-0.01
Shares Outstanding 3,877.28M70.50M70.50M70.50M70.50M70.50M60.25M10.00M10.00M11.50M10.76M12.06M12.19M12.19M31.55M107.79M107.82M
Shares Outstanding (Entity)Shares Outstanding (Entity.) 3,877.28M70.50M70.50M70.50M70.50M70.50M60.25M10.00M10.00M11.50M11.50M12.09M12.19M12.19M31.55M107.82M107.82M
EBITDA -0.75M-0.89M-1.03M-0.80M-1.01M-1.08M-1.14M-0.77M-0.62M-1.12M-26.23M-1.01M-1.15M-0.95M-2.29M-0.70M
Interest ExpensesInt Expense 0.14M0.09M0.10M0.10M0.12M0.10M0.12M0.23M0.26M0.30M0.27M0.27M0.26M0.26M0.07M0.07M
Tax Rate -128.63%35.82%